News

Double strike against cancer
Enlarge image

ResearchGermany

Double strike against cancer

13.06.2013 - German researchers have found a way to circumvent chemotherapy resistance in cancer cells.

A new therapeutic approach can take advantage of cancer cells' need to repair double-strand breaks in DNA, in order to overcome the tumour's resistance to chemotherapy (Science Transl. Medicine). According to the research group headed by Hans Christian from University Cologne, mutations in the ATM gene protect cancer cells from cell death during chemotherapy. ATM  is instrumental in initiating DNA repair and inducing cell death when repair is not possible in curse of the so-called DNA damage response (DDR).  

But now the researchers have found that the protection offered by ATM mutations comes at a cost – dependence on a DNA-repairing enzyme called DNA-PKcs (DNAdependent protein kinase catalytic subunit). In experiments with mouse and human cancer cells, Christian et al. proved that it's possible to exploit this weak spot to fight blood cancer and solid tumours. Treating the cells with drugs that block DNA-PKcs led to cancer cell death. Intriguingly, both healthy cells and cancer cells with normal ATM function can tolerate the loss of DNA-PKcs, suggesting few side effects. The findings hint that drugs designed to specifically kill ATM-deficient tumours could benefit cancer patients.   The dependence of ATM-defective cells on DNA-PKcs offers a window of opportunity for therapeutic intervention: Either pharmacological or genetic abrogation of DNAPKcs in ATM-defective cells led to the accumulation of DNA double-strand breaks and the subsequent CtBP-interactingprotein (CtIP)-dependent generation of large single-stranded DNA (ssDNA) repair intermediates. These ssDNA structures trigger proapoptotic signalling through the RPA/ATRIP/ATR/Chk1/p53/Puma axis, ultimately leading to the apoptotic demise of ATM-defective cells exposed to DNA-PKcs inhibitors such as Celgene Corp.'s compound CC115. According to the researchers, such DNA-PKcs inhibitors are effective as single agents against ATM-defective lymphomas in vivo. CC-115 binds to and inhibits the activity of DNA-PK (DNA-dependent protein kinase) and both raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2), which may lead to a reduction in cellular proliferation of cancer cells expressing DNA-PK and TOR.  

Christian told EuroBiotechNews that his group currently is in negotiation with Celgene which is currently in Phase I testing of CC115. "We would like to extend the trial to a ATM-stratified population of CCL patients," he said. ATM is overexpressed in 10% of blood cancers and 10% of carcinomas of the lungs, colon, and pancreas.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/double-strike-against-cancer.html

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • IMMUNICUM AB (S)33.00 SEK32.00%
  • ZEALAND PHARMA (DK)151.00 DKK4.86%
  • CYTOS (CH)0.46 CHF4.55%

FLOP

  • OREXO (S)53.25 SEK-28.76%
  • THERAMETRICS (CH)0.06 CHF-14.29%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)80.79 EUR53.2%
  • BIOTIE THERAPEUTICS (FI)0.22 EUR37.5%

FLOP

  • BIOTEST (D)26.60 EUR-61.7%
  • BIOTECH PHARMACON (N)9.30 NOK-46.9%
  • EVOCUTIS (UK)0.16 GBP-27.3%

TOP

  • ADOCIA (F)89.23 EUR535.1%
  • DBV TECHNOLOGIES (F)80.79 EUR324.1%
  • FORMYCON (D)28.54 EUR319.1%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.50 SEK-72.0%
  • NEOVACS (F)1.04 EUR-69.7%

No liability assumed, Date: 04.08.2015